Perfecseal Introduces New Packaging Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Perfecseal Introduces New Packaging Products
Perfecseal's high-barrier PVC-free blister-forming web, PerfecForm SkyBlue, is based on polyolefin chemistry, and its new high-barrier flow-wrap specification, PerfecPharm P232, is capable of achieving hermetic seals at the maximum speed capabilities of the top flow-wrap equipment.


Perfecseal has introduced a new high-barrier, PVC-free, blister-forming web, PerfecForm SkyBlue, designed to be cost effective and provide barrier properties to protect all but the highest barrier requirement product applications. This high-barrier blister film is based on polyolefin chemistry, rather than the chlorine chemistry used to produce PVC forming webs.

Unlike other barrier blister films, PerfecForm SkyBlue is manufactured via a co-extrusion process as a symmetrical structure. The thickness of the barrier layer, which is sandwiched between co-polyester, determines the overall barrier performance.

Perfecseal has also introduced a new high-barrier flow-wrap specification, PerfecPharm P232, which is capable of achieving hermetic seals at the maximum speed capabilities of the top flow-wrap equipment. “Perfecseal evaluated this product on high-speed Bosch flow-wrap equipment to assure this product would meet the desired performance level demanded by the healthcare market,” states Georgia Mohr, pharmaceutical director of Perfecseal, in a press release. “The P232 flow wrap material offers a large sealing window (140°C–200°C) and the potential to run at lower temperatures than traditional materials, yet seals hermetically at speeds exceeding 300 ppm.” Once again, Perfecseal delivers packaging solutions based on material science expertise.

Perfecseal, a division of Bemis Company, specializes in healthcare packaging and delivers packaging solutions based on material science expertise.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here